Three novel antimicrobial peptides found in the bean bug Riptortus pedestris showed potent activity against drug-resistant Gram-negative bacteria and saved mice from lethal E. coli sepsis at doses of 5 mg/kg.
Effective at >5 mg/kg in lethal sepsisRip-2, derived from the bean bug, saved mice from lethal E. coli septicemia at daily doses greater than 5 mg/kg — outperforming the parent peptide thanatin against ESKAPE pathogens.
What the researchers found
Three novel thanatin-like β-hairpin antimicrobial peptides (Rip-2, Rip-3, Rip-4) were discovered in the bean bug Riptortus pedestris through transcriptome mining. Homologs are widely distributed across the insect infraorder Pentatomomorpha.
Rip-2 shared structural similarity with thanatin and targeted the LptA protein, showing higher activity than thanatin against key Gram-negative ESKAPE pathogens. It demonstrated significant efficacy in a lethal mouse septicemia model caused by E. coli at daily doses >5 mg/kg. Rip-3 and Rip-4 had a different mechanism — membrane damage rather than LptA targeting. They showed strong selectivity against Bacillus and Mycobacterium species, did not induce bacterial resistance, and had different antimicrobial spectra.
Why it matters
Antimicrobial resistance is projected to cause millions of deaths annually if new antibiotics aren't developed. Insect antimicrobial peptides represent a largely untapped source of novel antibiotic candidates. The discovery that these bug-derived peptides can kill drug-resistant ESKAPE pathogens and save mice from lethal infections — while using mechanisms that don't easily trigger resistance — makes them promising templates for next-generation antibiotics.
How the study worked
Researchers used transcriptome mining to identify novel antimicrobial peptide genes in the bean bug Riptortus pedestris. The three identified peptides were expressed using a bacterial expression system. Antimicrobial activity was tested in vitro against various bacterial strains, and Rip-2 was further evaluated in vivo using a lethal E. coli septicemia model in mice. Mechanisms of action were characterized including LptA targeting and membrane damage assays.
What this study cannot tell us
The study is preclinical, with in vivo testing limited to a single mouse model (E. coli sepsis). Pharmacokinetics, toxicity, and stability of these peptides in mammalian systems are not fully characterized. The bacterial expression system may produce peptides with different properties than native insect peptides. Only one peptide (Rip-2) was tested in vivo. Clinical translation from insect peptides to human therapeutics faces significant development hurdles.
How to read the evidence
This is a preclinical discovery study with both in vitro and in vivo validation in a mouse model. The evidence is strong for early-stage drug discovery but has not progressed to clinical testing.
When this study was published
Published in 2024, this study represents the current frontier of insect-derived antimicrobial peptide discovery, an increasingly active area of antibiotic research.
The bigger picture
The search for antimicrobial peptides from insects is a growing field within antibiotic drug discovery. Insects have robust innate immune systems honed by millions of years of evolution, producing peptides optimized to kill bacteria. Thanatin-like peptides targeting the LptA protein of Gram-negative bacteria represent a particularly promising class because they attack an essential outer membrane assembly pathway that is difficult for bacteria to modify. This study expands the known diversity of this peptide family and identifies candidates with improved activity.
Questions still open
- Can Rip-2 be optimized for better pharmacokinetic properties while maintaining its ESKAPE pathogen activity?
- Could Rip-3/4's membrane-damage mechanism be combined with conventional antibiotics for synergistic effects?
- How do these insect peptides compare to other antimicrobial peptides currently in clinical development?
Common questions
How can bugs help us fight antibiotic resistance?
Could these insect peptides become real antibiotics?
Read the original research
Discovery of Novel Thanatin-like Antimicrobial Peptides from Bean Bug Riptortus pedestris.
Pharmaceutics, 16(11)
Citation
Panteleev, Pavel V; Teplovodskaya, Julia S; Utkina, Anastasia D; Smolina, Anastasia A; Kruglikov, Roman N; Safronova, Victoria N; Bolosov, Ilia A; Korobova, Olga V; Borzilov, Alexander I; Ovchinnikova, Tatiana V. (2024). Discovery of Novel Thanatin-like Antimicrobial Peptides from Bean Bug Riptortus pedestris.. Pharmaceutics, 16(11). https://doi.org/10.3390/pharmaceutics16111453